AUG 04, 2020 4:27 PM PDT

Erectile Dysfunction Drug Cures Critical COVID-19 Patients

WRITTEN BY: Annie Lennon

Critically ill patients who received COVID-19 drug candidate aviptadil (RLF-100) were able to make a rapid recovery from respiratory failure from COVID-19, according to pharmaceutical companies NeuroRX and Relief Therapeutics.

Typically used alongside phentolamine to treat erectile dysfunction, the first report on the drug's success comes from doctors in Houston Methodist Hospital. 

Although these early results are yet to be released, the report highlights the case of a 54-year-old man who contracted COVID-19 while receiving treatment for rejection of a double lung transplant. Within four days of treatment with RLF-100, he reportedly came off the ventilator. The companies say that similar results also came for 15 other patients treated under emergency use. 

More than this, the report supposedly highlights the rapid clearance of classic pneumonitis findings on x-rays, improved blood oxygen, and a 50% or greater average reduction in laboratory markers for inflammation by COVID-19. 

An independent research team at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, also showed that the drug candidate was able to prevent SARS coronavirus replication in human lung cells and monocytes in Petri dishes. 

Although promising results, due to the relatively small sample size, and other limitations, Jonathon Javitt, NeuroRx CEO and Chairman remains cautious. 

"If you ask me whether this is the cure to COVID, my answer is that I don't know, but it shows promise, and I hope so," says Javitt. "Of course, this is a small number [refering to patient data so far], and of course, testing that includes patients given placebos is needed."

Last week, the US Food and Drug Administration granted the drug an Expanded Access Protocol to treat respiratory distress from COVID-19. This means that the drug can be administered on an emergency basis to patients who are too ill to join a clinical trial and pregnant women. Meanwhile, Phase II/III trials involving 70 people are still ongoing. 

 

Sources: Clinical Trial ArenaTimes of Israel

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 11, 2021
Drug Discovery & Development
Could Mucus-Based Drugs Replace Antibiotics?
JUL 11, 2021
Could Mucus-Based Drugs Replace Antibiotics?
Researchers from the Copenhagen Center for Glycomics in Denmark have developed a way to produce healthy mucus artificial ...
JUL 15, 2021
Cannabis Sciences
Cannabis Terpenes Provide Pain Relief in Mice
JUL 15, 2021
Cannabis Terpenes Provide Pain Relief in Mice
Cannabis terpenes, the part of cannabis plants responsible for its smell and taste, may be able to relieve pain both by ...
JUL 27, 2021
Immunology
Rethinking Immune Responses Involved in Skin Hypersensitivity
JUL 27, 2021
Rethinking Immune Responses Involved in Skin Hypersensitivity
A study by immunologists at the University of Copenhagen has revealed a never-before-seen immune pathway invol ...
AUG 12, 2021
Drug Discovery & Development
Postpartum depression drug works through altering brain waves
AUG 12, 2021
Postpartum depression drug works through altering brain waves
     Postpartum depression is a form of depression that occurs after childbirth. This form of depres ...
SEP 07, 2021
Drug Discovery & Development
A giant step in treating growth disorders in children.
SEP 07, 2021
A giant step in treating growth disorders in children.
Hormone production and release is important in individuals of all ages but is especially important for children as hormo ...
SEP 26, 2021
Coronavirus
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
SEP 26, 2021
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
Humans can produce millions or even billions of antibodies, so only so many can be captured and screened. But those anti ...
Loading Comments...